Recent Updates
Recently added Catalysts

GGTA1 KO Thymokidney

Phase 1

ESRD (End-Stage Renal Disease) | Monoclonal antibody | Nephrology |United Therapeutics Corporation|Last Updated: May 27, 2026

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLEDDMCBiomarker
Total Trials1
Total Enrollment50
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT07224763Study to Evaluate the Safety and Efficacy of the GGTA1 KO Thymokidney in Patients With ESRDPHASE1 RECRUITING 50Jun 1, 2026Mar 1, 2076May 27, 20261 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Survival Rate of Patients with ESRD Receiving the GGTA1 KO Thymokidney at 24 Weeks Post Transplant
Day 0 (day of xenotransplantation) to 24 weeks post transplant

Participant survival rate at 24 weeks post transplant.

Survival Rate of the GGTA1 KO Thymokidney at 24 Weeks Post Transplant
Day 0 (day of xenotransplantation) to 24 weeks post transplant

GGTA1 KO Thymokidney survival rate at 24 weeks post transplant. GGTA1 KO Thymokidney failure is defined as GGTA1 KO Thymokidney nephrectomy.

Survival Time of Participants Receiving the GGTA1 KO Thymokidney
Day 0 (day of xenotransplantation) until death for any cause, assessed at least every 24 weeks after transplantation while the participant is alive, up to 50 years

Participant survival post transplant. Participant survival is defined as time from xenotransplantation to death for any cause.

Survival Time of the GGTA1 KO Thymokidney (Overall Survival)
Day 0 (day of xenotransplantation) until start of chronic dialysis, nephrectomy, or death, whichever occurs first, assessed at least every 24 weeks after transplantation while the participant is alive and the thymokidney is functional, up to 50 years

Overall survival of the GGTA1 KO Thymokidney post transplant. Overall survival time of the GGTA1 KO Thymokidney is defined as time from xenotransplantation to GGTA1 KO Thymokidney nephrectomy or death, whichever occurs first.

Survival Time of the GGTA1 KO Thymokidney (Death-censored Survival)
Day 0 (day of xenotransplantation) until start of chronic dialysis, nephrectomy, or death, whichever occurs first, assessed at least every 24 weeks after transplantation while the participant is alive and the thymokidney is functional, up to 50 years

Death-censored survival GGTA1 KO Thymokidney. Death-censored survival time of the GGTA1 KO Thymokidney is defined as time from xenotransplantation to GGTA1 KO Thymokidney nephrectomy censored for death.

GGTA1 KO Thymokidney Function Post Transplant (Endogenous GFR)
At 24 weeks post transplant

Endogenous measured GFR (24-hour urine creatinine clearance) at 24 weeks post transplant.

GGTA1 KO Thymokidney Function Post Transplant (Exogenous GFR)
At 24 weeks post transplant

Exogenous measured GFR (nuclear medicine GFR) at 24 weeks post transplant.

GGTA1 KO Thymokidney Function Post Transplant (Proliferative Responsiveness)
At 24 weeks post transplant

Proliferative responsiveness to source GGTA1 KO Pig versus third-party pig as measured by mixed lymphocyte reaction from baseline to 24 weeks post transplant.

Quality of Life in Participants Receiving the GGTA1 KO Thymokidney by EuroQol 5-Dimension 5-Level (EQ-5D-5L)
Baseline to 24 weeks post transplant

Change in the EQ-5D-5L from baseline to 24 weeks post transplant. The EQ-5D-5L questionnaire assesses health-related quality of life across 5 categories (Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression). Each category has 5 levels, ranging from 1 (no problems) to 5 (extreme problems or inability to perform the activity). Higher scores indicate a worse health outcome (more mobility issues, greater pain, more anxiety, etc).

Quality of Life in Participants Receiving the GGTA1 KO Thymokidney by Standardized Outcomes in Nephrology Life Participant (SONG-LP)
Baseline to 24 weeks post transplant

Change in SONG-LP from baseline to 24 weeks post transplant. The SONG-LP assesses participation in different life activities over the past month. The minimum score (worst outcome) is 4 (if all responses are "1" - Never) and the maximum score (best outcome) is 20 (if all responses are "5" - Always). Higher scores indicate a better health outcome (greater ability to participate in activities).

Quality of Life in Participants Receiving the GGTA1 KO Thymokidney by Kidney Transplant Questionnaire (KTQ)
Baseline to 24 weeks post transplant

Change in KTQ from baseline to 24 weeks post transplant. Each question in the KTQ is scored on a 1 to 7 scale with: 1 = worst outcome (eg, "A very great deal of trouble or distress" / "All of the time") and 7 = best outcome (eg, "No trouble or distress" / "None of the time"). Higher scores indicate a better outcome, meaning less distress, fewer symptoms, and better well-being.

Quality of Life in Participants Receiving the GGTA1 KO Thymokidney by Patient Global Impression of Change (PGI-C)
At 24 weeks post transplant

PGI-C at 24 weeks post transplant. The PGI-C assesses a patient's perception of improvement or worsening over time. The minimum score (best outcome) is 1 ("Very Much Improved") and the maximum score (worst outcome) is 7 ("Very Much Worse"). Higher scores indicate a worse health outcome (greater worsening).

Incidence of Treatment-Emergent Adverse Events (Safety of the GGTA1 KO Thymokidney)
Baseline until last visit, assessed at least every 24 weeks after transplantation while the participant is alive and the thymokidney is functional, up to 50 years, or for 1 year after nephrectomy if required

Incidence of adverse events and serious adverse events; all-cause mortality.

Incidence of Proteinuria
Day 0 (day of xenotransplantation) until last visit, assessed at least every 24 weeks after transplantation while the participant is alive and the thymokidney is functional, up to 50 years, or for 1 year after nephrectomy if required

Incidence of proteinuria from Day 0.

Incidence of Zoonotic Infection
Day 0 (day of xenotransplantation) until last visit, assessed at least every 24 weeks after transplantation while the participant is alive and the thymokidney is functional, up to 50 years, or for 1 year after nephrectomy if required

Incidence of zoonotic infection from Day 0.

Incidence of Opportunistic Infection
Day 0 (day of xenotransplantation) until last visit, assessed at least every 24 weeks after transplantation while the participant is alive and the thymokidney is functional, up to 50 years, or for 1 year after nephrectomy if required

Incidence of opportunistic infection from Day 0.

Unlock Study Endpoints
Study Design & Arms
AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
GGTA1 KO ThymokidneyEXPERIMENTALParticipants will receive GGTA1 KO Thymokidney
Interventions
NameTypeDescription
GGTA1 KO ThymokidneyBIOLOGICALPorcine kidney containing an intentional genomic alteration and thymic tissue autograft for xenotransplantation
Unlock Study Design Details
Eligibility Criteria
Age Range40 Years — 70 Years
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria for all Participants (Groups 1 and 2): 1. Provide voluntarily informed consent to participate in the study and for lifetime follow-up. 2. Have a diagnosis of ESRD at the time of informed consent. 3. Hemodialysis dependent for a minimum of 6 months and has a functioning arterial-v...

Countries:United States
Unlock Eligibility Criteria
Recent Changes (Last 90 Days)
LOWMay 28, 2026NCT07224763startDate: changed
LOWMay 28, 2026NCT07224763startDate: changed
LOWMay 26, 2026NCT07224763primaryCompletionDate: changed
LOWMay 24, 2026NCT07224763studyFirstPostDate: changed